Free Trial

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares Sold by Flossbach Von Storch SE

BioNTech logo with Medical background

Flossbach Von Storch SE cut its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 3.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,259,631 shares of the company's stock after selling 147,212 shares during the period. BioNTech accounts for approximately 1.7% of Flossbach Von Storch SE's portfolio, making the stock its 21st largest holding. Flossbach Von Storch SE owned approximately 1.78% of BioNTech worth $387,882,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bank of New York Mellon Corp increased its position in shares of BioNTech by 18,892.9% in the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after purchasing an additional 694,691 shares during the last quarter. GF Fund Management CO. LTD. increased its position in shares of BioNTech by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company's stock worth $229,000 after purchasing an additional 453 shares during the last quarter. OneDigital Investment Advisors LLC bought a new position in shares of BioNTech in the first quarter worth approximately $288,000. Vontobel Holding Ltd. increased its position in shares of BioNTech by 2.3% in the first quarter. Vontobel Holding Ltd. now owns 21,882 shares of the company's stock worth $1,993,000 after purchasing an additional 497 shares during the last quarter. Finally, Goodman Advisory Group LLC bought a new position in shares of BioNTech in the first quarter worth approximately $105,000. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $138.00 target price on shares of BioNTech in a research note on Wednesday, June 25th. Truist Financial reaffirmed a "buy" rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. The Goldman Sachs Group assumed coverage on BioNTech in a research note on Thursday, May 29th. They issued a "neutral" rating and a $110.00 target price for the company. JPMorgan Chase & Co. cut their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Finally, Citigroup reaffirmed a "buy" rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, BioNTech has a consensus rating of "Moderate Buy" and an average price target of $137.91.

Read Our Latest Stock Report on BioNTech

BioNTech Price Performance

BNTX traded up $0.53 during trading on Thursday, hitting $112.31. The company's stock had a trading volume of 214,854 shares, compared to its average volume of 941,700. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. The business's fifty day simple moving average is $103.17 and its 200 day simple moving average is $106.86. The firm has a market capitalization of $27.00 billion, a price-to-earnings ratio of -33.04 and a beta of 1.29. BioNTech SE Sponsored ADR has a twelve month low of $76.53 and a twelve month high of $131.49.

BioNTech Company Profile

(Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Further Reading

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Should You Invest $1,000 in BioNTech Right Now?

Before you consider BioNTech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.

While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines